LIFECORE BIOMEDICAL, INC. financials

LFCR CIK 0001005286

Source: EDGAR filings · Built 2026-06-02T03:27:04Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2025FY 2024FY 2023FY 2022FY 2021
Free Cash Flow 3.63M -13.62M -18.27M -48.82M -2.90M
EBITDA 4.81M -9.22M -890.00K -8.62M 6.27M 11.04M
Working Capital 58.72M 55.50M 42.16M 54.59M -59.91M 43.45M
Net Debt 132.13M 129.87M 125.28M 76.72M 112.20M 191.64M
Gross Margin 31.37% 31.27% 32.63% 27.10% 35.11% 38.60%
Operating Margin -0.97% -13.38% -6.90% -21.11% -10.60% -8.75%
Net Margin -23.78% -30.04% 9.37% -96.41% -104.89% -32.01%
Return on Equity (ROE) 126.47% -2897.98% 106.17% 2353.74% -132.90% -15.99%
Return on Assets (ROA) -7.74% -16.18% 4.73% -39.27% -42.49% -6.43%
Current Ratio 3.49× 2.84× 2.08× 2.39× 0.66× 1.43×
Debt-to-Equity -10.53× 103.39× 11.82× -22.65× 1.29× 0.95×
Effective Tax Rate -1.91% -0.11% 1.92% -0.48% 25.19% 21.32%
Cash Conversion Ratio -0.41× 0.01× 0.02× 0.18× 0.19× -0.51×
Accruals Ratio -0.11× -0.16× 0.05× -0.32× -0.34× -0.10×
SBC % of Revenue 7.51% 7.88% 4.83% 3.50% 2.34% 3.33%
CapEx Coverage 1.98× -0.02× 0.01× -0.86× 0.85×
Free Cash Flow Per Share $0.10 $-0.39 $-0.50 $-1.66 $-0.10

Valuation Metrics

Concept FY 2025FY 2025FY 2024FY 2023FY 2022FY 2021
P/E Trailing (Diluted) 17.03×
P/FCF 84.16×
FCF Yield 1.19%
EV / EBITDA 91.24× 64.35× 49.14×
P/S 4.06× 1.93× 1.34× 2.33× 2.62× 3.48×
P/B 186.24× 15.18× 3.32× 1.74×

Income Statement

Concept FY 2025FY 2025FY 2024FY 2023FY 2022FY 2021
Cost of Goods and Services Sold 51.83M 88.57M 86.41M 75.28M 72.20M 61.94M
Gross Profit 23.69M 40.30M 41.85M 27.98M 39.07M 38.94M
Research and Development Expense 4.96M 8.26M 8.57M 8.74M 7.84M 6.68M
Selling, General and Administrative Expense 19.46M 44.05M 40.46M 38.97M 34.66M 27.72M
Operating Expenses 50.69M 49.78M 50.86M 47.76M
Operating Income (Loss) -733.00K -17.25M -8.84M -21.80M -11.79M -8.82M
Income Tax Expense (Benefit) 337.00K 43.00K 183.00K 308.00K -5.21M -6.35M
Net Income (Loss) Attributable to Parent -17.96M -38.72M 12.01M -99.56M -116.72M -32.29M
Earnings Per Share, Basic $-0.54 $-1.27 $0.39 $-3.32 $-3.97 $-1.10
Weighted Average Number of Shares Outstanding, Basic 37.37M 34.82M 30.47M 29.96M 29.47M 29.29M
Earnings Per Share, Diluted $-0.54 $-1.27 $0.33 $-3.32 $-3.97 $-1.10
Weighted Average Number of Shares Outstanding, Diluted 37.37M 34.82M 36.66M 29.96M 29.47M 29.29M

Balance Sheet

Concept FY 2025FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 17.47M 8.27M 8.46M 19.09M 991.00K 763.00K
Assets, Current 82.29M 85.68M 81.03M 93.88M 116.67M 145.30M
Assets 232.18M 239.34M 253.96M 253.54M 274.70M 501.88M
Long-term Debt 142.24M 130.44M 124.67M 84.84M 98.18M 164.90M
Liabilities, Current 23.57M 30.18M 38.87M 39.29M 176.58M 101.85M
Long-term Debt, Excluding Current Maturities 100.82M 84.26M 0 164.90M
Liabilities 198.12M 191.91M 200.06M 218.46M 186.88M 299.94M
Stockholders' Equity Attributable to Parent -14.20M 1.34M 11.31M -4.23M 87.82M 201.95M
Common Stock, Shares, Outstanding 37.48M 37.03M 30.56M 30.32M 29.51M 29.33M

Cash Flow Statement

Concept FY 2025FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 7.33M -206.00K 257.00K -17.44M -22.59M 16.47M
Payments to Acquire Property, Plant, and Equipment 3.70M 13.41M 18.39M 26.23M 19.26M
Net Cash Provided by (Used in) Investing Activities 6.30M -6.42M -18.39M -4.81M 79.96M -12.31M
Net Cash Provided by (Used in) Financing Activities -4.43M 6.42M 7.51M 39.70M -57.02M -3.42M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (LFCR CIK 0001005286), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

MDB

MONGODB, INC.

TRTX

TPG RE Finance Trust, Inc.

CRNC

CERENCE INC.